Health

  • October 13, 2026

    Troutman Grows Life Sciences Litigation Group In Philly, NY

    A pair of attorneys specializing in healthcare and life sciences litigation recently moved their practices to Troutman Pepper Locke LLP's offices in Philadelphia and New York City.

  • October 13, 2026

    1st Circ. Revives Amgen Migraine Drug Risk Label Suit

    A mother in Massachusetts is entitled to pursue a new theory of liability against drugmaker Amgen Inc. over the death of her 25-year-old son after he took the company's then-recently approved migraine medication Aimovig in 2018, the First Circuit has found.

  • October 13, 2026

    Haynes Boone Launches In San Diego For 4th Calif. Location

    Haynes Boone has opened its first San Diego office to deepen its life sciences, healthcare and technology capabilities and has selected a co-chair of its biotechnology practice to lead its fourth workplace in California.

  • October 13, 2026

    Health Co. Mirra-Access Hits Ch. 11 To Deal With $400M Loan

    Healthcare company Mirra-Access is seeking Chapter 11 protection in a Florida bankruptcy court with more than $100 million in debt and plans to restructure a loan facility with a firm tied to Franklin Templeton.

  • October 13, 2026

    Dentons Adds K&L Gates Lawyer To Healthcare Practice In DC

    Dentons has hired a former K&L Gates LLP counsel as a partner in its Washington, D.C., office, where he will advise pharmaceutical, biotechnology and medical device companies on a range of matters related to regulatory and transactional oversight, the firm announced.

  • October 13, 2026

    McDermott Hires Ex-Greenberg RE Atty For NYC Office

    McDermott Will & Schulte has hired former Greenberg Traurig LLP real estate finance attorney Paul K. Kovachev to be a partner in its transactions practice group in New York City, the firm announced.

  • October 13, 2026

    Laid-Off Workers Can't Sue Amid Board Appeal, Feds Say

    The federal government asked a Maryland federal court to throw out a suit brought by more than 300 former federal workers who say their agency layoffs were politically motivated, arguing the workers must pursue their claims through an administrative process before heading to court.

  • October 09, 2026

    DOJ Aims To 'Attack Fraud From All Angles' Via New Division

    The U.S. Department of Justice's new fraud division has issued fresh guidance on its prosecution methodology, with the division's head directing prosecutors to seize assets before indictments and pursue upward variances in sentencing guidelines in some cases as part of a stated push to use the division's "full arsenal of criminal statutes" in combating fraud.

  • October 09, 2026

    TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M

    Two clinical-stage biotechnology firms, TRex Bio and Retension Pharmaceuticals, hit the public markets on Friday after raising a combined $162 million in their initial public offerings.

  • October 09, 2026

    Expert's Failure To Identify Doctors Dooms Texas Med Mal Suit

    A Texas appellate court has tossed a medical malpractice lawsuit accusing three doctors of failing to diagnose a woman's brain cyst, holding that the plaintiff's expert report failed to identify which physicians allegedly caused the woman's injuries.

  • October 09, 2026

    9th Circ. Says AmeriBen Data Breach Enough To Allege Injury

    The Ninth Circuit on Friday revived a proposed data breach class action alleging health plan administrator AmeriBen unlawfully revealed patients' information, ruling the disclosures were enough to sustain a lawsuit even if the underlying information might seem "mundane."

  • October 09, 2026

    Gene Therapy Patent Suit Against Sarepta Comes To Close

    Sarepta Therapeutics Inc. no longer has to face a lawsuit accusing it of infringing a University of Pennsylvania gene therapy patent licensed by clinical-stage biotechnology company Regenxbio Inc. after the parties told a Delaware federal judge they agreed to end the case.

  • October 09, 2026

    DA Pans Mangione's Double Jeopardy Bid In NY Murder Case

    New York prosecutors on Friday panned Luigi Mangione's bid to dismiss his state murder case, arguing that his guilty plea to federal stalking charges does not subject him to unlawful double jeopardy, as the second-degree murder charge is meant to prevent a different kind of "harm or evil."

  • October 09, 2026

    Estate Says Insurer Must Cover Fatal Hyperbaric Chamber Suit

    The parents of a 5-year-old killed in a hyperbaric chamber explosion and the center where he was receiving the therapy urged a Michigan federal court to reject an insurer's bid to avoid defending the center, saying that insurance coverage is warranted in the family's wrongful-death suit.

  • October 09, 2026

    Woman Says Emory Healthcare's Inaction Led To Son's Death

    A Georgia woman sued Emory University and Emory Healthcare Inc. in state court, alleging they refused repeated requests to check on her son, who was later found unresponsive in a hospital parking deck and died of an accidental fentanyl overdose.

  • October 09, 2026

    Latham-Led Consonance Clinches $1.35B Healthcare Fund

    Latham & Watkins LLP-advised healthcare private equity shop Consonance Capital Partners on Friday revealed that it closed its latest fund with $1.35 billion of investor commitments.

  • October 09, 2026

    'A Moral Hazard': Kalshi Drug Trial Bets Spark Ethical Qualms

    Kalshi Inc. opening prediction markets for clinical drug trials has raised a host of compliance concerns for attorneys, including the risk of insider trading among the wide swaths of stakeholders in the know about the trials, as well as the danger of compromising the trials themselves.

  • October 09, 2026

    Logistics Cos. Can't Pause Tobacco Fee Suit

    A Connecticut federal judge on Friday shut down two logistics companies' bid to stay discovery in a case claiming they didn't properly reimburse employees who paid a health plan fee for tobacco use, ruling a pause wasn't warranted given the suit's history.

  • October 09, 2026

    ERISA Recap: 6 Notable Decisions From September

    The Tenth and Seventh circuits issued published opinions in two union retirement disputes, while the Sixth Circuit found that the Commonwealth of Kentucky's lawsuit against pharmacy benefit managers does not belong in state court, citing colorable federal preemption arguments. Here's more on those decisions and three other notable rulings involving the Employee Retirement Income Security Act that came down in September.

  • October 09, 2026

    Feds Again Turn To 9th Circ. In Fight Over ICE Facility

    The Trump administration said Friday it will ask the Ninth Circuit to overturn a trial court decision requiring ICE to give independent monitors access to conduct inspections and electronic records for detained immigrants at a lockup in Adelanto, California, where a judge has twice called for conditions to be improved.

  • October 09, 2026

    Squires Grants 4 PTAB Petitions, Rejects 3 In New Drop

    U.S. Patent and Trademark Office Director John Squires has instituted four new America Invents Act reviews at the Patent Trial and Appeal Board and turned down three in his newest mass order.

  • October 09, 2026

    Eli Lilly Lobs 4 Suits Alleging Illegal Weight Loss Drug Sales

    Eli Lilly and Co. has sued an Arizona weight loss clinic and three online sellers, alleging they are illegally selling products containing the pharmaceutical giant's investigational molecule that has not yet been approved for use in any drug, endangering consumers in a mockery of safety guidelines.

  • October 09, 2026

    IVF Genetic Test Class Can't Prove Inaccurate Results

    A New Jersey federal judge has thrown out a proposed class action alleging a genetic testing company misled consumers about the accuracy of in-vitro fertilization patient tests, ruling the plaintiffs failed to show they actually received inaccurate results.

  • October 09, 2026

    Hospitals Ask Court To Block Revised Plan For 340B Rebates

    The American Hospital Association and four safety-net hospitals in Maine sued the Trump administration Friday to block plans to establish a rebate system in the 340B drug discount program, alleging it violates procedural requirements and threatens hospital finances.

  • October 08, 2026

    Taro Pharma Says MDL Deal Bars States' Duplicative Claims

    Taro Pharmaceuticals USA asked a Connecticut federal judge to toss generic-drug price-fixing claims brought by a coalition of states on behalf of consumers that are duplicative of claims the consumers have already resolved through settlements in separate multidistrict litigation.

Expert Analysis

  • DOJ Healthcare Declination Offers Self-Disclosure Checklist

    Author Photo

    The U.S. Department of Justice's declination of criminal charges against Campus Eye Management signals that its new self-disclosure policy provides a real path for healthcare companies to avoid criminal exposure, but that path is paved with speed, transparency and operational remediation, says Jonathan Porter at Husch Blackwell.

  • Series

    Being In A Band Made Me A Better Lawyer

    Author Photo

    Playing shows in storied New York City venues and rehearsing with my bandmates in poorly ventilated rooms helped develop the professional qualities I rely on as a litigator, including an ability to collaborate with strong-minded equals and the determination to treat each client with singular focus, says Eliad Shapiro at Herrick Feinstein.

  • Opinion

    Correctional Healthcare Requires Clearer Legal Standards

    Author Photo

    As the correctional healthcare industry increasingly faces financial instability due to litigation, the U.S. Bureau of Prisons should develop clear standards for constitutionally adequate care for incarcerated patients, says Susanne Moore at Blackstone Trial Group.

  • Mich. Ruling Gives Consumer Protection Law Its Teeth Back

    Author Photo

    The Michigan Supreme Court's recent decision in Attorney General v. Eli Lilly, overruling key holdings in two earlier cases, means that Michigan businesses can no longer defeat allegations of deceptive conduct under the state's consumer protection law simply by pointing to any governmental regulation of the business, say attorneys at DiCello Levitt.

  • Series

    Law School's Missed Lessons: Surviving A Long Trial

    Author Photo

    Most of law school trial advocacy is geared toward the sprint of trying a short case, but beyond managing a cross-examination or closing argument, effectively handling the marathon of a lengthy trial requires the ability to maintain composure, organization and credibility with the jury, says Mihir Elchuri at Hirschler.

  • AI Chatbot's Medical Claims Highlight Enforcement Risks

    Author Photo

    The Pennsylvania State Board of Medicine's recent lawsuit against Character Technologies, arguing that an artificial intelligence chatbot engaged in the unlicensed practice of medicine, may provide other state licensing boards with a road map for going after AI platforms, and counsel should advise clients to calibrate compliance accordingly, say attorneys at Cooley.

  • 7th Circ. Ruling May Reduce Litigation Risk For Text Marketers

    Author Photo

    The recent Seventh Circuit holding in Steidinger v. Blackstone Medical Services that unwanted marketing text messages are not telephone calls under the Telephone Consumer Protection Act may strengthen companies' responses to presuit demand letters and early-stage litigation claims premised on do-not-call text theories, say attorneys at Holland & Knight.

  • How Calif. Ruling Defines Drug Cos.' R&D Responsibilities

    Author Photo

    The California Supreme Court's recent ruling in the Gilead Tenofovir Cases, which held that drugmakers have no duty to bring allegedly safer alternatives to market more quickly, is a win for pharmaceutical companies — but not a grant of blanket immunity for all early-stage drug development decisions, say attorneys at King & Spalding.

  • Calif. Justices' Ruling Reshapes Midcase Appeal Strategy

    Author Photo

    The California Supreme Court's recent decision in Maniago v. Desert Cardiology Consultants holds that voluntary dismissal cannot be used as a shortcut to appellate review of interlocutory orders, resolving a long-running appellate split and pushing litigants to use alternative procedural tools, says Josh Patashnik at Ashurst Perkins Coie.

  • Midyear Trends, Takeaways As Securities Class Actions Surge

    Author Photo

    High numbers of securities class actions through June suggest filings will stay elevated, with factors like changing enforcement attitudes, media scrutiny and the proliferation of potential defendants serving as both cause and effect in increased litigation involving AI-related disclosures, health and tech companies, and foreign issuers, say attorneys at Alston & Bird.

  • Series

    Going To Hardcore Shows Makes Me A Better Lawyer

    Author Photo

    While government contracts law and the hardcore scene may seem entirely unrelated, in my experience, both are about community, focus, being prepared for the unexpected and managing chaos, says Isaac Natter at Fluet.

  • Brace For Expanding Scrutiny Of Dark Patterns In Healthcare

    Author Photo

    Recent reporting and regulatory developments highlight growing concern surrounding so-called dark patterns in healthcare — user interface designs that improperly influence consumer decision-making — and represent an important evolution of how healthcare professionals should evaluate consent processes, say attorneys at Clark Hill.

  • How Home Infusion Providers Can Adapt To Enrollment Pause

    Author Photo

    Recent Centers for Medicare & Medicaid Services moratoria on new enrollments of home health agencies, medical equipment companies and hospices make home infusion providers' compliance obligations more complex and ambiguous, requiring new careful consideration of specific enrollment requirements and limitations, say attorneys at Quarles & Brady.

  • AI Data Mining Is Changing FCA Enforcement

    Author Photo

    With False Claims Act investigations increasingly emerging from statistical anomalies identified by data miners, companies need to consider what conclusions an outsider armed with artificial intelligence might draw from public-facing data and be ready to explain any anomalies if questions arise, say attorneys at Cohen & Gresser.

  • Lessons From 5 Months Of DOJ Corporate Policy Deals

    Author Photo

    Recent declinations and prosecution agreements between the U.S. Department of Justice and corporations since the March unveiling of the corporate enforcement and voluntary disclosure policy provide takeaways for management considering how to respond to corporate misconduct, says Brendan Quigley at Baker Botts.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.